Astellas Pharma Unsp/Adr (ALPMY) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr03/2026	Next Qtr06/2026	Fiscal Yr03/2026	Fiscal Yr03/2027
Average Estimate	N/A	N/A	0.63	1.12
Number of Estimates	0	0	2	2
High Estimate	N/A	N/A	0.64	1.37
Low Estimate	N/A	N/A	0.63	0.87
Prior Year	0.27	0.40	1.09	0.63
Growth Rate Est. (year over year)	+369,900.00%	+249,650.00%	-42.20%	+77.78%

Earnings History - Surprises*

	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025
Reported	$0.44	$0.30	$0.40	$0.27
Estimate	N/A	N/A	N/A	N/A
Difference	N/A	N/A	N/A	N/A
Surprise	N/A	N/A	N/A	N/A

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

3.89

3 Mths Ago9

3.89

2 Mths Ago9

3.67

1 Mth Ago9

3.60

Current10

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	9	9	9	10
	4	4	3	3
Holds	5	5	6	7

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Analysts’ forecast returns, recommendations and yields for all stocks in the S&P/TSX SmallCap Index

Small caps to watch: Aecon, Maple Leaf Foods, Tecsys and more

Thursday’s analyst upgrades and downgrades

Wednesday’s analyst upgrades and downgrades

number cruncher

Seven Canadian oil producers set to benefit from rising prices

Bullish on Mullen Group Ltd.

Top non-resource stocks on the TSX with strong insider signals

Berkshire Hathaway shares have largest slide since Buffett’s resignation